Inherited Retinal Dystrophy Due to RPE65 Mutations

Ophthalmology

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Gene Therapy

1100%

+ 1 programs with unclassified modality

Ophthalmology is a $3.7B market with a mature, consolidating portfolio dominated by glaucoma treatments and emerging corneal/retinal therapies.

$3.7B marketMature→ Stable30 products15 companies

Key Trends

Glaucoma therapeutics (prostaglandin analogs, adrenergic agents) represent 60%+ of spending but face patent cliffs 2028-2034
Innovative mechanisms (NGF agonists, LFA-1 antagonists, RTKIs) gaining traction in dry eye and retinal disease segments
Heavy trial activity (2,656 total) skewed toward Phase 4 (369) and Phase 3 (442), indicating mature clinical development landscape

Career Verdict

Ophthalmology offers stable mid-career opportunities with strong Commercial and Medical Affairs salaries, but limited innovation catalysts and significant patent cliff risk warrant careful timing of entry.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#	Product	Company	Revenue	Share	Stage	Trend	LOE
1	LUMIGAN (Bimatoprost)	AbbVie	$697M	19%	LOE_APPROACHING	Declining
2	OXERVATE (Cenegermin-BKBJ)	Unspecified	$493M	13%	PEAK	Stable
3	XIIDRA (Lifitegrast)	Bausch + Lomb	$473M	13%	PEAK	Stable	7.6yr
4	INLYTA (Axitinib)	Pfizer	$467M	13%	PEAK	Growing	11.2yr
5	HUMIRA (Adalimumab)	AbbVie	$258M	7%	LOE_APPROACHING	Declining

#1LUMIGAN

$697M

AbbVie·LOE_APPROACHING

#2OXERVATE

$493M

Unspecified·PEAK

#3XIIDRA

$473M

Bausch + Lomb·PEAK7.6yr

#4INLYTA

$467M

Pfizer·PEAK11.2yr

#5HUMIRA

$258M

AbbVie·LOE_APPROACHING

Drug Class Breakdown

Prostaglandin Analogs (Bimatoprost)

$697M(19%)

mature, losing exclusivity

Nerve Growth Factor Agonists

$493M(13%)

peak growth in corneal disease

LFA-1 Antagonists (Dry Eye)

$473M(13%)

sustained peak sales

Receptor Tyrosine Kinase Inhibitors

$467M(13%)

expanding in retinal indications

Alpha-2 Adrenergic Agonists

$362M(10%)

mature, multiple LOE approaching

Combination Therapies (Brimonidine/Timolol)

$232M(6%)

mature, losing exclusivity

Complement Inhibitors

$223M(6%)

mature immunology approach

Career Outlook

Stable

Ophthalmology offers predictable mid-career growth with strong Commercial ($158K) and Medical Affairs ($247K) compensation but faces structural headwinds: patent cliffs 2028-2034 eliminate $97M in revenue, glaucoma franchise maturity limits blockbuster potential, and modest trial volume (2,656) signals incremental R&D expansion. Best suited for professionals seeking stable roles in established therapeutic areas rather than disruptive innovation.

Breaking In

Enter via Clinical Operations or Commercial analyst roles at CROs (Syneos 210 jobs) or large diagnostics players (Labcorp 904) to build domain expertise before targeting pharma MSL/Medical Affairs positions.

For Experienced Professionals

Experienced professionals should prioritize Medical Affairs and Market Access roles leveraging mature market knowledge; avoid product-specific expertise in glaucoma due to patent cliff concentration, and consider adjacent areas (retinal, corneal) where innovation catalysts remain.

In-Demand Skills

Glaucoma/dry eye clinical expertise and key opinion leader relationshipsRegulatory navigation for mature small-molecule formulations and device combinationsMarket access and reimbursement strategy (high generic/biosimilar pressure)

Best For

Medical Science Liaison (MSL) — strong $247K average salary, KOL interface criticalCommercial/Brand Manager — competitive $158K salaries, established product lifecycle managementClinical Operations Manager — high hiring volume (409 jobs), trial coordination in Phase 4-heavy pipeline

Hiring Landscape

$59K-$247K

Ophthalmology hiring (3,202 jobs) is distributed across diagnostics/devices (Labcorp 904, Abbott 348) and pharma commercial functions rather than concentrated in R&D. Top pharmaceutical employers (Pfizer 60, AstraZeneca 100, Regeneron 168) show modest pharma-specific headcount relative to market size, suggesting outsourced CRO and distributor dependency. Medical Affairs ($247K avg salary) commands premium compensation, signaling high barrier to entry but strong mid-career upside.

3,202

Open Roles

Companies Hiring

Departments

Top Hiring Companies

Labcorp

904

Abbott

348

MicroAire Surgical Instruments

245

Regeneron

168

Danaher

219

By Department

Clinical Operations(13%)

$150K

Commercial(10%)

$158K

Medical Affairs(3%)

$247K

R&D(6%)

$145K

Engineering(9%)

$112K

Clinical Operations and Commercial roles offer entry-level stability ($150K-$158K); Medical Affairs commands premium salaries ($247K) but requires advanced credentials; limited R&D hiring (207 jobs) suggests constrained innovation investment.

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

SPARK BiopharmaKorea - Seoul

2 programs

AAV2-hRPE65v2,voretigene neparvovec-rzylPhase 3Gene Therapy1 trial

AAV2-hRPE65v2N/A1 trial

Active Trials

NCT03602820Active Not Recruiting41Est. Jan 2030

NCT00999609Active Not Recruiting31Est. Jan 2030

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

SPARK BiopharmaAAV2-hRPE65v2,voretigene neparvovec-rzyl

SPARK BiopharmaAAV2-hRPE65v2

Clinical Trials (2)

Total enrollment: 72 patients across 2 trials

NCT00999609 SPARK BiopharmaAAV2-hRPE65v2,voretigene neparvovec-rzyl

Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

Start: Oct 2012Est. completion: Jan 203031 patients

Phase 3Active Not Recruiting

NCT03602820 SPARK BiopharmaAAV2-hRPE65v2

Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)

Start: Jun 2015Est. completion: Jan 203041 patients

N/AActive Not Recruiting

Related Jobs in Ophthalmology

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals

1 companies competing in this space

Related Indications

Glaucoma(223)Cataract(220)Open Angle Glaucoma(168)Myopia(162)Dry Eye(154)Age-Related Macular Degeneration(149)Neovascular Age-related Macular Degeneration(113)Dry Eye Disease(106)Dry Eye Syndromes(86)Macular Degeneration(76)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.